tiprankstipranks
Trending News
More News >
Tevogen Bio Holdings Inc. (TVGN)
:TVGN

Tevogen Bio Holdings (TVGN) AI Stock Analysis

Compare
284 Followers

Top Page

TV

Tevogen Bio Holdings

(NASDAQ:TVGN)

33Underperform
Tevogen Bio Holdings faces substantial financial risks due to consistent losses and high leverage, which are typical in its industry. Technical analysis indicates a bearish trend, and valuation metrics show speculative investment characteristics. However, the recent corporate event involving a strategic agreement provides a positive outlook for operational advancements, slightly balancing the financial and technical concerns.

Tevogen Bio Holdings (TVGN) vs. S&P 500 (SPY)

Tevogen Bio Holdings Business Overview & Revenue Model

Company DescriptionTevogen Bio Holdings (TVGN) is a biotechnology company focused on the development and commercialization of innovative immunotherapies for the treatment of viral infections and cancers. The company's core products include advanced therapeutic solutions designed to harness the power of the immune system to target and eliminate disease-causing cells. Tevogen Bio operates within the biotech sector, leveraging cutting-edge research and development to deliver novel treatments that address unmet medical needs.
How the Company Makes MoneyTevogen Bio Holdings generates revenue primarily through the development and commercialization of its proprietary immunotherapy products. The company's revenue model includes income from product sales, licensing agreements, and strategic partnerships with pharmaceutical companies and research institutions. Additionally, Tevogen Bio may receive funding through grants and collaborations aimed at advancing its research initiatives. As the company progresses through clinical trials and secures regulatory approvals, sales of approved therapies are expected to be a significant revenue stream. Strategic alliances and partnerships also play a crucial role in expanding market reach and driving earnings.

Tevogen Bio Holdings Financial Statement Overview

Summary
Tevogen Bio Holdings is facing significant financial challenges with consistent operational losses, high leverage due to negative equity, and negative cash flow from operations. These factors suggest substantial financial risks, which are common in the biotech industry during early development stages.
Income Statement
Tevogen Bio Holdings has shown consistent negative EBIT and net income over the years with no revenue reported. The lack of revenue growth and recurring losses highlight challenges in achieving profitability. This is typical for biotechnology firms in the development phase but poses a risk to financial stability.
Balance Sheet
15
The company exhibits a high debt-to-equity ratio due to negative equity, reflecting high leverage and potential financial instability. Total assets have decreased significantly, and equity is negative, indicating financial distress. The negative equity also reflects accumulated losses over time.
Cash Flow
Tevogen's cash flow statement reveals negative operating and free cash flows, indicating cash burn typical of early-stage biotech companies. However, financing activities provided positive cash flow, suggesting reliance on external funding for operations. The absence of positive cash flow from operations poses sustainability risks.
Breakdown
Dec 2023Dec 2022Dec 2021
Income StatementTotal Revenue
0.000.000.00
Gross Profit
0.000.000.00
EBIT
-13.72M-4.62M
EBITDA
188.71K-953.08K-28.75K
Net Income Common Stockholders
-67.33K4.41M-15.60M
Balance SheetCash, Cash Equivalents and Short-Term Investments
8.84K129.19K7.12M
Total Assets
17.04M357.14M7.66M
Total Debt
1.63M40.01M23.48M
Net Debt
1.62M39.88M16.36M
Total Liabilities
17.73M15.06M24.15M
Stockholders Equity
-695.80K342.08M-16.49M
Cash FlowFree Cash Flow
-1.38M-694.44K-5.38M
Operating Cash Flow
-1.38M-215.40K-5.27M
Investing Cash Flow
342.92M-109.73K
Financing Cash Flow
-341.66M7.50K12.50M

Tevogen Bio Holdings Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.06
Price Trends
50DMA
1.09
Negative
100DMA
1.19
Negative
200DMA
1.08
Negative
Market Momentum
MACD
-0.02
Negative
RSI
50.45
Neutral
STOCH
65.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Positive. The current price of 1.06 is above the 20-day moving average (MA) of 1.01, below the 50-day MA of 1.09, and below the 200-day MA of 1.08, indicating a neutral trend. The MACD of -0.02 indicates Negative momentum. The RSI at 50.45 is Neutral, neither overbought nor oversold. The STOCH value of 65.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TVGN.

Tevogen Bio Holdings Risk Analysis

Tevogen Bio Holdings disclosed 1 risk factors in its most recent earnings report. Tevogen Bio Holdings reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Tevogen Bio Holdings Peers Comparison

Overall Rating
UnderperformOutperform
Sector (64)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
$12.61B9.797.95%16985.69%12.77%-3.98%
52
Neutral
$208.77M-85.03%-15.39%19.42%
51
Neutral
$237.58M-222.36%-86.28%-476.70%
48
Neutral
$216.37M-173.41%22.99%
41
Neutral
$246.65M-174.85%-71.53%
40
Underperform
$199.20M-43.76%
33
Underperform
$185.73M-124.74%-20.39%
* Financial Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TVGN
Tevogen Bio Holdings
1.06
0.07
7.07%
CDXS
Codexis
2.51
-1.02
-28.90%
CDTX
Cidara Therapeutics
21.50
8.06
59.97%
CRVS
Corvus Pharmaceuticals
3.56
1.88
111.90%
NVCT
Nuvectis Pharma
8.96
1.77
24.62%
CRGX
CARGO Therapeutics, Inc.
4.08
-16.16
-79.84%

Tevogen Bio Holdings Corporate Events

Business Operations and Strategy
Tevogen Bio Signs Agreement with CD 8 Technology
Positive
Apr 17, 2025

On April 17, 2025, Tevogen Bio Holdings Inc. announced a Master Services and Facilities Agreement with CD 8 Technology Services LLC to access specialized manufacturing facilities for cell therapy production. This agreement is a strategic move to enhance Tevogen’s in-house production capabilities, aligning with its long-term strategy to accelerate development timelines, maintain operational agility, and control costs, thereby overcoming significant capital barriers typically faced in building GMP capabilities.

Spark’s Take on TVGN Stock

According to Spark, TipRanks’ AI Analyst, TVGN is a Underperform.

Tevogen Bio Holdings faces significant financial challenges, with operational losses and high leverage being key risks. Technical analysis indicates a bearish trend, and valuation metrics reflect the speculative nature typical of biotech firms in early development stages. However, recent funding announcements provide a positive outlook for strategic advancements, offering some mitigation to the financial risks.

To see Spark’s full report on TVGN stock, click here.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.